Cointime update: China’s National Medical Products Administration has approved 泊基奥仑赛注射液 (brand name: 赛泊华), a CAR-T therapy developed by Beijing Immunochina Biopharmaceutical Co., Ltd., for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. The indication covers diffuse large B-cell lymphoma not otherwise specified, grade 3b follicular lymphoma and high-grade B-cell lymphoma.
NMPA Approves Beijing Immunochina’s CAR-T Therapy for Large B-Cell Lymphoma
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
18m ago
Huobi HTX Lists TMO/USDT Perpetual Contract With Up to 20x Leverage
1h ago
Binance to Launch USDT Perpetual Contracts for Six TradFi Assets
1h ago
Vitalik: Young Investors Favor Digital Assets, Modern Platforms Should Adopt Housing-Like Traits
1h ago
Liquid Capital’s Yi Lihua: Build OTC Capabilities, Jensen Huang Incident to Spur Talent Returning to China
2h ago
US Spot Ethereum ETFs See $29.1M Net Outflow
2h ago
DBS Partners With Circle to Expand USDC Access for Asian Institutions